| MMR mRNA phenotype |
CRCs (n) / observed phenotypic frequencies |
Gender |
Tumor Stage (n) |
Invasion in |
Tumor site |
ANT (n) / observed phenotypic frequencies |
| lymph node |
nerve |
vessel |
| M |
F |
I |
II |
III |
N |
Y |
N |
Y |
N |
Y |
rt |
rc |
si |
lf |
n.a... |
|
| hMSH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| r2 |
23 / 0.7667 |
12 |
11 |
2 |
11 |
10 |
12 |
11 |
7 |
16 |
10 |
13 |
8 |
8 |
3 |
1 |
3 |
22 / 0.7857 |
| R2 |
7 / 0.2333 |
5 |
2 |
2 |
4 |
1 |
6 |
1 |
5 |
2 |
7 |
0 |
2 |
3 |
2 |
0 |
0 |
6 / 0.2143 |
| hMLH1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| r1 |
12 / 0.3871 |
7 |
5 |
1 |
4 |
7 |
4 |
8 |
2 |
10 |
5 |
7 |
2 |
6 |
2 |
0 |
2 |
11 / 0.3548 |
| R1 |
19 / 0.6129 |
10 |
9 |
4 |
11 |
4 |
15 |
4 |
11 |
8 |
13 |
6 |
8 |
5 |
4 |
1 |
1 |
20 / 0.6452 |
| hMSH6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| r6 |
12 / 0.3871 |
7 |
5 |
0 |
9 |
6 |
5 |
7 |
4 |
8 |
6 |
6 |
3 |
4 |
3 |
0 |
2 |
6 / 0.2000 |
| R6 |
19 / 0.6129 |
10 |
9 |
5 |
6 |
5 |
14 |
5 |
9 |
10 |
12 |
7 |
7 |
7 |
3 |
1 |
1 |
24 / 0.8000 |
| hPMS2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| p2 |
31 / 1.0000 |
16 |
14 |
5 |
15 |
11 |
19 |
12 |
13 |
18 |
18 |
13 |
10 |
11 |
6 |
1 |
3 |
30 / 1.0000 |
| P2 |
0 / 0.0000 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 / 0.0000 |
n, number of cases, r2, r1, r6, p2, MMR/control mRNA ratios <1; R2, R1, R6, P2, MMR mRNA ratios ≥1; M, male; F, female; N, no; Y, yes;, rt, right; rc, rectum; si, sigma; lf,
left; n.a., not available. |
